On July 19, Mindray and Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) held a strategic cooperation signing ceremony at Mindray's headquarters in Shenzhen. 

Li Zaiwen, Senior Vice President of Mindray, Zhao Yuxiang, General Manager of China, Luo Xiaoliang, General Manager of China In Vitro Diagnostics, Deng Wei, Marketing Director of China In Vitro Diagnostics, Xiao Guohua, Business Director of In Vitro Diagnostics Biochemical and Immunology Product Lines, Wang Haichun, Marketing Manager of Biochemical Products in China, Zou Zuojun, Chairman of BSBE, Liang Hongjun, Chairman of China National Pharmaceutical Investment, Vice Chairman of Jiuqiang Biologicals, and Sheng Dan, Executive Vice President of BSBE, were present in this signing ceremony.

Mr. Li Zaiwen said that BSBE is committed to the research, development, production and sales of in vitro diagnostic reagents, and has gained the trust of many customers with stable product quality and created a good brand image. BSBE and Mindray have been cooperating for many years, and have a good foundation of cooperation and mutual trust. Under the new situation, the two sides have opened an all-round cooperation, which can more fully utilize the complementary advantages of the products and is of great strategic significance.

Zou Zuojun, Chairman of BSBE said that Mindray represents our country's national medical industry, and BSBE is honored to become a partner with Mindray, and the long-term cooperation between the two sides is based on the mutual reinforcement of products, and even more so on the recognition of each other's corporate culture. It is believed that through the joint promotion of both parties, expanding the scope of cooperation and conducting more extensive and in-depth exploration, it will make greater contribution to the progress of the entire industry and create greater value.

At the event, the two sides carried out full exchanges and discussions on this strategic cooperation. Both sides agreed to carry out all-round strategic cooperation in R&D, production, manufacturing and sales. It is hoped that through the cooperation, the overall operational efficiency of both parties will be further enhanced, operational costs will be reduced, mutual benefits and common development will be realized, more comprehensive and better services will be provided to hospitals, patients and the whole industry, so that more people can share the social value of quality life care.